ARIZ needs your help and vote to advance in Buzz of Bio contest. Click here to vote!

ARIZ Precision Medicine honored to participate in Johnson & Johnson Innovation’s Quick Pitch at JPM 2020

February 20, 2020

ARIZ Precision Medicine was honored to be selected as one of nine companies worldwide to participate in Johnson & Johnson Innovation’s Quick Pitch at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2020.  ARIZ CEO Lonnie Bookbinder presented information about the Company’s breakthrough, lead drug candidate for lung cancer treatment.  Pictured here with Dr. Bookbinder are Dr. Brad Niles, ARIZ COO and VP of R&D (right), and Kevin Nagle, ARIZ Investor and Advisor (left), following their presentation to Johnson & Johnson External Innovation leadership.

ARIZ Precision Medicine is a pre-clinical drug development company targeting the root cause of cancers, using RNA Interference to block the production of a validated cancer-causing proteins.  The company has shown that >90% of lung cancer cells (A549) in culture can be eliminated with a single low dose. ARIZ is performing proof-of-concept studies in animal models of lung cancer and other pre-clinical studies in preparation for IND-enabling studies, which need to be performed before entering human clinical trials.  ARIZ is located in Davis, CA and affiliated with University of California, Davis as a participant in the UCD Venture Catalyst DRIVE program.